Loading viewer...
investor_presentation
Format: PDF investor_presentation
Johnson & Johnson investor presentation dated July 2021.
2Q 2021 Investor Update 2Introduction
Vice President, Investor Relations
Safe Harbor Statement
INTRODUCTIONThispresentation includes forward -looking statements within themeaning ofthePrivate Securities Litigation Reform Actof1995 .Any statements, other than statements ofhistorical fact, including, without limitation, our
financial guidance and related projections and statements regarding ourability tomeet such projections intheanticipated timeframe, ifatall;statements regarding continued procurement ofAV7909 under ourexisting
contract with BARDA ;thefulldelivery in2021 ofvaccines procured under theJuly 2021 ACAM 2000 ®option exercise ;thepotential award ofanew procurement contract forraxibacumab ;thestrength ofthenaloxone
market and thetiming and number ofnaloxone competitor entrants expected byyear end;thetiming oftheanticipated appellate decision onrelated pending patent litigation ;progress across thevaccines,
therapeutics, and devices portfolios and anticipated timing and number ofregulatory submissions ;thestrength ofourCDMO business unit and demand forbiologics services ;capacity expansion inourCDMO business
portfolio ;timing ofCDMO revenues, ourCDMO backlog and opportunity funnel ;thestability oftheU.S.government’s priority forprocuring solutions topublic health threats ;thedurability ofourbusiness and growth
potential ;remaining ontrack with respect toour2024 strategy ;capital expenditures and total contract value ;and any other statements containing thewords “will,” “believes,” “expects,” “anticipates,” “intends,” “plans,”
“targets,” “forecasts,” “estimates” and similar expressions inconjunction with, among other things, discussions oftheCompany’s outlook, financial performance orfinancial condition, financial and operation goals,
product sales, government development orprocurement contracts orawards, government appropriations, manufacturing capabilities, and thetiming ofcertain clinical trials and regulatory approvals areforward -looking
statements .These forward -looking statements arebased onourcurrent intentions, beliefs and expectations regarding future events .Wecannot guarantee that any forward -looking statement willbeaccurate .
Investors should realize that ifunderlying assumptions prove inaccurate orunknown risks oruncertainties materialize, actual results could differ materially from ourexpectations .Investors are, therefore, cautioned notto
place undue reliance onany forward -looking statement .Any forward -looking statements speak only asofthedate ofthispresentation, and, except asrequired bylaw, wedonotundertake toupdate any forward -
looking statement toreflect new information, events orcircumstances .There areanumber ofimportant factors that could cause ouractual results todiffer materially from those indicated bysuch forward -looking
statements, including thecontinued exercise ofdiscretion byBARDA toprocure additional doses ofAV7909 prior toapproval bytheFDA;ourability tonegotiate follow -onprocurement contracts forAV7909 and other
Preview truncated — download the full document for the complete content.
earnings_deck
investor_presentation
20 Pages
CyberArk Software
First Midwest Bancorp Old National Merger 2021
investor_presentationinvestor_presentation
26 Pages
First Midwest Bancorp, Inc. / Old National Bancorp